Milestone Pharmaceuticals Inc. - Common Shares, no par value (MIST)

CUSIP: 59935V107

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
-7,634,652
Put/Call ratio
517%
SEC-reported price per share
$2.02
Number of holders
79
Value change
-$15,312,984
Number of buys
47
Open additional details 1 more signal available
Number of sells
18
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
124,217,096

Security key

59935V107

Report period

Q4 2025

Institutions

79

Top holders

10

Ownership snapshot

Top reported holders of MIST - Milestone Pharmaceuticals Inc. - Common Shares, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Propel Bio Management, LLC
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G 13F 3/4/5 Lead comparable stake: 9.9% 13D/G row: Propel Bio Management, LLC Showing 1-6 of 15 holder rows.

Quick read

Propel Bio Management, LLC leads the comparable SEC ownership view at 9.9%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Propel Bio Management, LLC's linked filing trail.
Comparable ownership Top 5
Propel Bio Management, LLC 9.9%
Pavaki Capital Management LLC 7.3%
INTEGRATED CORE STRATEGIES (US) LLC 0.6%
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.6%
ORBIMED ADVISORS LLC 2.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Propel Bio Management, LLC
13D/G 13F
Company
9.9%
$21,001,011
8,861,186 shares
$0 11 Jul 2025
Pavaki Capital Management LLC
13D/G
7.3%
$11,878,881
9,067,848 shares
$0 31 Dec 2025
INTEGRATED CORE STRATEGIES (US) LLC
13D/G
0.6%
$396,161
322,082 shares
$0 31 Mar 2025
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
5.6%
$13,952,000
6,976,000 shares
30 Sep 2025
ORBIMED ADVISORS LLC
13F
Company
13F
2.6%
$6,443,656
3,221,828 shares
30 Sep 2025
MORGAN STANLEY
13F
Company
13F
2.4%
$5,938,134
2,969,067 shares
30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
79
Shares
26,494,301
Rows available
79
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
61
Q4 2025 holders
79
Holder diff
18
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .